Open sidebar
Reports

Vaccine Coverage (Children): 2nd dose

Description
Report on COVID-19 vaccination coverage in England, for all patients aged 5-15 registered with practices that use TPP SystmOne software, focussing on second doses which are due (i.e. where first dose was recorded at least 14 weeks ago). UPDATE: we are no longer updating these reports on a regular basis. If you do rely on these reports and data releases in your own work, please get in touch at the email address below.
Contact
Get in touch and tell us how you use this report or new features you'd like to see: team@opensafely.org
First published
08 Jul 2022
Last released
10 Oct 2022
Links

OpenSAFELY COVID Vaccine coverage report: second doses for 5 to 15 year olds

OpenSAFELY is a new secure analytics platform for electronic patient records built on behalf of NHS England to deliver urgent academic and operational research during the pandemic.

Since December 2020 we have been reporting on COVID-19 vaccination coverage (for patients aged 16 and over) in England using data from 40% of general practices that use TPP electronic health record software. In September 2021, the COVID vaccination programme was extended to 12-15 year olds. The Living with Covid guidance was updated in February 2022 to advise that vaccines would be offered to children between the ages of 5 and 11 from Spring 2022. As such, we are now regularly reporting on vaccination coverage for children between the age of 5 and 15.

The data requires careful interpretation and there are a number of caveats, please refer to our peer-reviewed publications (https://doi.org/10.3399/BJGP.2021.0376) for further details. While the publication describes an analysis of vaccine uptake in those 16 and over, it is relevant here as the same methodology has been used to generate our vaccine coverage reports for 5-15 year olds.

The full analytical methods behind the latest results in this report are available here.

Vaccines approved for use in children

The 30 microgram dose of the Pfizer BioNTech COVID-19 vaccine BNT162b2 was approved for use in 12-15 year olds in June 2021. In December 2021, the MHRA approved a 10 microgram dose for children aged 5-11 years. Where the paediatric formulation is not available, 10 micrograms (0.1ml) of the diluted adult vaccine may be used as an alternative. The Moderna vaccine has also been approved for use in 12-17 year olds.

More information regarding vaccines approved for use is available in The Green Book, chapter 14a, see specifically the "Vaccine Effectiveness" (p.6-7) and "Dosing and Schedule" (p. 12-13) sections.

Second doses

Second doses are recommended to occur within 8 weeks for children at high risk and within 12 weeks for all other children (see p. 13 in The Green Book, chapter 14a). To accommodate short delays in the administration of second doses, in this report we consider an individual to be 'due' to receive their second dose if their first dose more than 14 weeks ago. Anyone who has not had their second dose by 14 weeks is described as 'overdue'.

Please note: This report is intended to highlight any differences between population subgroups in receiving second doses, only including those which are due (i.e. where at least 14 weeks has passed since the first dose) unless otherwise stated. It is therefore NOT a comprehensive view of all second doses given to date - to see these figures please refer to the first dose report.

Report last updated 07 Oct 2022

Second dose vaccinations included up to 10 Aug 2022 inclusive

Only 5-15 year olds who had their first dose between the start of the campaign (4th August 2021) and 7 weeks ago (04 May 2022) are included in the 'due' group.

Contents

Group definitions

  • Patient age is calculated on the date of extraction from date of birth; note that, to minimise risk of disclosure, all dates of birth are rounded down to the first of the month in OpenSAFELY.
  • The patients who are 'In a risk group' have been identified using the criteria in Table 4 of the Green Book and codelists from SARS-CoV2 (COVID-19) Vaccine Uptake Reporting Specification Collection 2020/2021 (v1.5.3) as distributed by PRIMIS. This includes patients with:
    • Immunosuppression
    • Chronic kidney disease
    • Chronic liver disease
    • Chronic heart disease
    • Chronic respiratory disease
    • Chronic neurological disease (including stroke/TIA, cerebral palsy, or MS)
    • Asplenia or dysfunction of the spleen
    • Asthma
    • Diabetes
    • Severe mental illness
    • Learning disabilities
    • Pregnancy
  • Any patient who does not belong to a risk group mentioned above are described as 'Not in a risk group'.

Brand counts

Note that the total in this table may not be identical to that provided elsewhere and percentages may not sum to 100%. There are several aspects of the recorded data and analysis that impact on these totals:

  • It is not always possible to determine the vaccine type given; these patients are removed from the brand totals
  • Occasionally patients have more than one brand recorded on the same day; these patients are removed from the brand totals
  • We round to seven to mitigate against risk of disclosure; these totals are calculated from previously rounded numbers
  • Second doses are counted here whether they are 'due' or not
Second doses as at 10 Aug 2022 % second doses as at 10 Aug 2022
Group Vaccine brand
5-11 Pfizer (30 micrograms) 854 1.10
Pfizer (10 micrograms) 76433 98.86
Other 28 0.04
12-15 Pfizer (30 micrograms) 439831 97.20
Pfizer (10 micrograms) 12495 2.76
Other 168 0.04

Notes

  • Patient counts are rounded to nearest 7

  • 'Other' vaccines are Oxford-AZ or Moderna

  • For the brand totals, second doses given in these timescales are counted whether or not they were 'due' according to the relevant dosing schedule at the time.

Second dose coverage by first dose brand

The percentage of second doses received by first dose brand are provided below.

Note that these figures are raw proportions and do not take into account how many are due; this may vary substantially by brand.

Second doses (% of all vaccinated): 62.2% (529,739)

Second doses (% of Pfizer (30 micrograms) first doses): 72.3% (440,685)

Second doses (% of Pfizer (10 micrograms) first doses): 36.7% (88,928)

Second doses (% of Other first doses): 46.7% (196)

Mixed doses of Pfizer (30 micrograms/10 micrograms) (% of fully vaccinated): 1.1% (5810)

Mixed doses of Pfizer and Oxford-AZ/Moderna (% of fully vaccinated): 0.0% (0)

Back to top

Cumulative second dose vaccination figures among 5-11 population

Please refer to footnotes below table for information.

Second Doses due at 10 Aug 2022 (n) Second doses overdue (n) Second doses given (n) Second doses given (% of due) Total population
Category Group
overall overall 119,203 50,673 68,530 57.5 2,022,195
Sex F 57,400 24,367 33,033 57.5 985,061
M 61,803 26,299 35,504 57.4 1,037,106
Ethnicity (broad categories) Black 1,603 812 791 49.3 65,716
Mixed 3,577 1,470 2,107 58.9 78,589
Other 3,178 1,442 1,736 54.6 57,953
South Asian 11,655 5,117 6,538 56.1 195,132
Unknown 11,466 4,851 6,615 57.7 208,852
White 87,724 36,974 50,750 57.9 1,415,925
Ethnicity (detailed categories) African 1,120 574 546 48.8 42,602
Bangladeshi or British Bangladeshi 882 406 476 54.0 16,611
Caribbean 98 49 49 50.0 7,175
Chinese 1,302 574 728 55.9 10,934
Other 1,869 868 1,001 53.6 47,026
Other Asian 2,212 931 1,281 57.9 37,177
British or Mixed British 82,432 34,720 47,712 57.9 1,243,886
Indian or British Indian 6,888 2,884 4,004 58.1 64,589
Irish 189 70 119 63.0 3,920
Other Black 385 196 189 49.1 15,953
Other White 5,124 2,191 2,933 57.2 168,063
Other mixed 1,400 560 840 60.0 30,030
Pakistani or British Pakistani 1,666 896 770 46.2 76,741
Unknown 11,459 4,844 6,615 57.7 208,866
White + Asian 1,288 518 770 59.8 18,319
White + Black African 504 238 266 52.8 12,852
White + Black Caribbean 385 154 231 60.0 17,423
Index of Multiple Deprivation (quintiles) 1 Most deprived 18,515 9,128 9,387 50.7 484,596
2 20,258 9,065 11,193 55.3 392,560
3 23,548 9,912 13,636 57.9 380,037
4 24,724 10,136 14,588 59.0 350,637
5 Least deprived 27,027 10,311 16,716 61.8 329,077
Unknown 5,124 2,114 3,010 58.7 85,253
Risk status In a risk group 16,457 5,782 10,675 64.9 118,839
Not in a risk group 102,746 44,891 57,855 56.3 1,903,328
Brand of first dose Other 42 28 14 33.3 56
Pfizer (10 micrograms) 117,502 49,861 67,641 57.6 216,986
Pfizer (30 micrograms) 1,414 658 756 53.5 1,841
Unknown 245 126 119 48.6 287

Footnotes:

  • Patient counts rounded to the nearest 7.
  • Only persons who are currently registered and had their first dose at least 14 weeks ago are included in the 'due' group.

Second Doses Overdue Among 5-11 Population

Second doses which have not been given at least 14 weeks since the first dose

Error bars indicate possible error caused by rounding

Back to top

Cumulative second dose vaccination figures among 12-15 population

Please refer to footnotes below table for information.

Second Doses due at 10 Aug 2022 (n) Second doses overdue (n) Second doses given (n) Second doses given (% of due) Total population
Category Group
overall overall 607,131 157,325 449,806 74.1 1,184,008
Sex F 297,332 75,999 221,333 74.4 577,899
M 309,757 81,312 228,445 73.7 606,039
Ethnicity (broad categories) Black 11,445 4,718 6,727 58.8 41,258
Mixed 14,805 4,298 10,507 71.0 37,891
Other 13,104 3,717 9,387 71.6 32,739
South Asian 50,652 14,805 35,847 70.8 113,365
Unknown 42,791 10,717 32,074 75.0 89,698
White 474,292 119,063 355,229 74.9 868,980
Ethnicity (detailed categories) African 7,819 3,241 4,578 58.5 25,704
Bangladeshi or British Bangladeshi 4,690 1,687 3,003 64.0 9,968
Caribbean 840 343 497 59.2 4,690
Chinese 3,759 889 2,870 76.4 6,832
Other 9,359 2,828 6,531 69.8 25,928
Other Asian 10,885 3,283 7,602 69.8 22,925
British or Mixed British 440,811 109,704 331,107 75.1 764,512
Indian or British Indian 20,314 4,347 15,967 78.6 35,168
Irish 980 224 756 77.1 2,380
Other Black 2,786 1,134 1,652 59.3 10,857
Other White 32,494 9,128 23,366 71.9 102,088
Other mixed 5,803 1,596 4,207 72.5 14,525
Pakistani or British Pakistani 14,756 5,481 9,275 62.9 45,283
Unknown 42,777 10,717 32,060 74.9 89,698
White + Asian 4,410 1,064 3,346 75.9 8,568
White + Black African 2,310 833 1,477 63.9 6,678
White + Black Caribbean 2,289 805 1,484 64.8 8,120
Index of Multiple Deprivation (quintiles) 1 Most deprived 102,256 38,059 64,197 62.8 278,796
2 105,623 32,067 73,556 69.6 227,899
3 120,526 31,024 89,502 74.3 225,673
4 125,979 27,566 98,413 78.1 213,038
5 Least deprived 135,737 24,332 111,405 82.1 207,158
Unknown 16,968 4,263 12,705 74.9 31,360
Risk status In a risk group 49,805 12,565 37,240 74.8 89,859
Not in a risk group 557,284 144,746 412,538 74.0 1,094,072
Brand of first dose Other 294 140 154 52.4 322
Pfizer (10 micrograms) 17,087 5,712 11,375 66.6 25,242
Pfizer (30 micrograms) 589,624 151,424 438,200 74.3 607,460
Unknown 84 35 49 58.3 98

Footnotes:

  • Patient counts rounded to the nearest 7.
  • Only persons who are currently registered and had their first dose at least 14 weeks ago are included in the 'due' group.

Second Doses Overdue Among 12-15 Population

Second doses which have not been given at least 14 weeks since the first dose

Error bars indicate possible error caused by rounding

Summary

Second Doses due at 10 Aug 2022 (n) Second doses given (% of due) Second doses given (n) Second doses overdue (n) Total population
5-11 119,203 57.5 68,530 50,673 2,022,195
12-15 607,131 74.1 449,806 157,325 1,184,008

Time to second dose

Find below plots showing cumulative percentage of time to second dose (all brands), for the 5-11 and 12-15 groups.

Cumulative plot of time to second dose among 5-11 population

by all

Cumulative plot of time to second dose among 12-15 population

by all